Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US10022447 | UPJOHN | Solid pharmaceutical compositions containing pregabalin |
Nov, 2026
(3 years from now) | |
US8945620 | UPJOHN | Solid pharmaceutical compositions containing pregabalin |
Nov, 2026
(3 years from now) | |
US9144559 | UPJOHN | Solid pharmaceutical compositions containing pregabalin |
Nov, 2026
(3 years from now) | |
US9144559
(Pediatric) | UPJOHN | Solid pharmaceutical compositions containing pregabalin |
May, 2027
(4 years from now) | |
US10022447
(Pediatric) | UPJOHN | Solid pharmaceutical compositions containing pregabalin |
May, 2027
(4 years from now) | |
US8945620
(Pediatric) | UPJOHN | Solid pharmaceutical compositions containing pregabalin |
May, 2027
(4 years from now) |
Drugs and Companies using PREGABALIN ingredient
Market Authorisation Date: 11 October, 2017
Treatment: Treatment of postherpetic neuralgia; Treatment of neuropathic pain associated with diabetic peripheral neuropathy
Dosage: TABLET, EXTENDED RELEASE;ORAL
13
United States
1
Portugal
1
Uruguay
1
Guatemala
1
Spain
1
Brazil
1
Costa Rica
1
IB
1
New Zealand
1
Dominican Republic
1
Norway
1
Argentina
1
Morocco
1
Peru
1
China
1
Taiwan, Province of China
1
Korea, Republic of
1
Hong Kong
1
EA
1
Tunisia
1
South Africa
1
Japan
1
Canada
1
Cyprus
1
Slovenia
1
ME
1
Israel
1
Poland
1
Australia
1
RS
1
Ecuador
1
Denmark
1
Netherlands
1
European Union
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic